How Can We Engineer CAR T Cells to Overcome Resistance?

Chimeric antigen receptor (CAR) T cell therapy has achieved unrivalled success in the treatment of B cell and plasma cell malignancies, with five CAR T cell products now approved by the US Food and Drug Administration (FDA). However, CAR T cell therapies for solid tumours have not been nearly as suc...

Descripción completa

Detalles Bibliográficos
Autores principales: Glover, Maya, Avraamides, Stephanie, Maher, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141613/
https://www.ncbi.nlm.nih.gov/pubmed/34040345
http://dx.doi.org/10.2147/BTT.S252568
_version_ 1783696399522594816
author Glover, Maya
Avraamides, Stephanie
Maher, John
author_facet Glover, Maya
Avraamides, Stephanie
Maher, John
author_sort Glover, Maya
collection PubMed
description Chimeric antigen receptor (CAR) T cell therapy has achieved unrivalled success in the treatment of B cell and plasma cell malignancies, with five CAR T cell products now approved by the US Food and Drug Administration (FDA). However, CAR T cell therapies for solid tumours have not been nearly as successful, owing to several additional challenges. Here, we discuss mechanisms of tumour resistance in CAR T cell therapy and the emerging strategies that are under development to engineer CAR T cells to overcome resistance.
format Online
Article
Text
id pubmed-8141613
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-81416132021-05-25 How Can We Engineer CAR T Cells to Overcome Resistance? Glover, Maya Avraamides, Stephanie Maher, John Biologics Review Chimeric antigen receptor (CAR) T cell therapy has achieved unrivalled success in the treatment of B cell and plasma cell malignancies, with five CAR T cell products now approved by the US Food and Drug Administration (FDA). However, CAR T cell therapies for solid tumours have not been nearly as successful, owing to several additional challenges. Here, we discuss mechanisms of tumour resistance in CAR T cell therapy and the emerging strategies that are under development to engineer CAR T cells to overcome resistance. Dove 2021-05-19 /pmc/articles/PMC8141613/ /pubmed/34040345 http://dx.doi.org/10.2147/BTT.S252568 Text en © 2021 Glover et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Glover, Maya
Avraamides, Stephanie
Maher, John
How Can We Engineer CAR T Cells to Overcome Resistance?
title How Can We Engineer CAR T Cells to Overcome Resistance?
title_full How Can We Engineer CAR T Cells to Overcome Resistance?
title_fullStr How Can We Engineer CAR T Cells to Overcome Resistance?
title_full_unstemmed How Can We Engineer CAR T Cells to Overcome Resistance?
title_short How Can We Engineer CAR T Cells to Overcome Resistance?
title_sort how can we engineer car t cells to overcome resistance?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141613/
https://www.ncbi.nlm.nih.gov/pubmed/34040345
http://dx.doi.org/10.2147/BTT.S252568
work_keys_str_mv AT glovermaya howcanweengineercartcellstoovercomeresistance
AT avraamidesstephanie howcanweengineercartcellstoovercomeresistance
AT maherjohn howcanweengineercartcellstoovercomeresistance

Ejemplares similares